abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Ulcerative Colitis · Diabetes Mellitus, Type 2
Eli Lilly and
Eli Lilly and Company
Eli Lilly and drug portfolio — 42 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
55,860 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Lilly Corporate Center, Indianapolis, Indiana 46285, US
- Employees
- 55,860
- Programs
- 62
- Drugs
- 42
- Patents
- 0
Eli Lilly and pipeline
Portfolio lens on 42 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Eli Lilly and drug portfolio — 42 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Eli Lilly and's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Eli Lilly and's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
baricitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Eli Lilly and's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
donanemab
Nervous system (N06)Nervous system (N06) compound in Eli Lilly and's portfolio. Molecular target: Amyloid-beta precursor protein.
- Target
- Amyloid-beta precursor protein
- Mechanism
- Beta amyloid A4 protein disrupting agent
-
drotrecogin alfa (activated)
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Eli Lilly and's portfolio. Molecular target: Coagulation factor V.
- Target
- Coagulation factor V
- Mechanism
- Coagulation factor V inhibitor
-
duloxetine
Nervous system (N06)Nervous system (N06) compound in Eli Lilly and's portfolio. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Eli Lilly and in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Eli Lilly and's portfolio.
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
Development asset linked to Eli Lilly and in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin glargine
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin lispro
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
lebrikizumab
Dermatologicals (D11)Dermatologicals (D11) compound in Eli Lilly and's portfolio. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
mirikizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Eli Lilly and's portfolio. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
necitumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
olaratumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor alpha.
- Target
- Platelet-derived growth factor receptor alpha
- Mechanism
- Platelet-derived growth factor receptor alpha antagonist
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
Development asset linked to Eli Lilly and in public FDA and regional records.
-
propranolol
Cardiovascular system (C07)Cardiovascular system (C07) compound in Eli Lilly and's portfolio. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
ramucirumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.
- Target
- Vascular endothelial growth factor receptor 2
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
-
selpercatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET.
- Target
- Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET
- Mechanism
- Tyrosine-protein kinase receptor RET inhibitor
-
tadalafil
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: cGMP-specific 3',5'-cyclic phosphodiesterase.
- Target
- cGMP-specific 3',5'-cyclic phosphodiesterase
- Mechanism
- Phosphodiesterase 5A inhibitor
-
teriparatide
Systemic hormonal preparations (H05)US regulatory status: approved. Molecular target: Parathyroid hormone/parathyroid hormone-related peptide receptor.
- Target
- Parathyroid hormone/parathyroid hormone-related peptide receptor
- Mechanism
- Parathyroid hormone receptor agonist
-
testosterone
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor agonist
-
tirzepatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist